UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Annals of oncology, 2015-09, Vol.26 (9), p.1883-1889

2015

Volltextzugriff (PDF)

1947P Predictors and outcomes of recurrent retroperitoneal liposarcoma: New insights into its recurrence patterns

Annals of oncology, 2023-10, Vol.34, p.S1044-S1044

2023

Volltextzugriff (PDF)

Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial

Annals of oncology, 2021-02, Vol.32 (2), p.218-228

2021

Volltextzugriff (PDF)

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

Annals of oncology, 2013-07, Vol.24 (7), p.1777-1785

2013

Volltextzugriff (PDF)

1410P Efficacy of fruquintinib plus paclitaxel (F+PTX) in patients (pts) with prior immunotherapy (prior-IO): Subgroup analysis from FRUTIGA study

Annals of oncology, 2024-09, Vol.35, p.S881-S882

2024

Volltextzugriff (PDF)

648P An open-label, MRCT phase I/II study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of first-in-class bi-ligand-drug conjugate CBP-1019 in patients (pts) with advanced solid tumors

Annals of oncology, 2024-09, Vol.35, p.S512-S513

2024

Volltextzugriff (PDF)

Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)

Annals of oncology, 2018-10, Vol.29, p.viii207-viii207

2018

Volltextzugriff (PDF)

77MO A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors

Annals of oncology, 2023-11, Vol.34, p.S1496-S1497

2023

Volltextzugriff (PDF)

220O RATIONALE-309: Effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC)

Annals of oncology, 2022-11, Vol.33, p.S1521-S1521

2022

Volltextzugriff (PDF)

VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy

Annals of oncology, 2022-01, Vol.33 (1), p.112-113

2022

Volltextzugriff (PDF)

Phase II trial of tepotinib vs sorafenib for treatment-naïve advanced hepatocellular carcinoma (HCC) in Asian patients

Annals of oncology, 2018-11, Vol.29, p.ix58-ix59

2018

Volltextzugriff (PDF)

584P Two-year update of the prospective evaluation of ColonAiQ (PreC) study

Annals of oncology, 2023-10, Vol.34, p.S426-S426

2023

Volltextzugriff (PDF)

1998P Antitumor activity and safety profile of trilaciclib in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC) receiving chemotherapy (TRACES): Updated results from TRACES

Annals of oncology, 2023-10, Vol.34, p.S1066-S1066

2023

Volltextzugriff (PDF)

853P The germline mutation landscape of DDR genes in Chinese patients with epithelial ovarian cancer

Annals of oncology, 2020-09, Vol.31, p.S635-S635

2020

Volltextzugriff (PDF)

1461P Analysis of MET gene alterations in cfDNA samples from a phase II study of savolitinib in patients (pts) with MET-amplified gastroesophageal junction adenocarcinomas or gastric cancer (GEJ/GC)

Annals of oncology, 2024-09, Vol.35, p.S905-S906

2024

Volltextzugriff (PDF)

392P A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer

Annals of oncology, 2022-11, Vol.33, p.S1595

2022

Volltextzugriff (PDF)

P-009Inhibition of Gastrointestinal Neuroendocrine Tumor by A New Marker of Normal Neuroendocrine Cells

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii3-ii3

2016

Volltextzugriff (PDF)

1458P Pucotenlimab (HX008) - humanized anti-PD-1 monoclonal antibody plus pemetrexed and platinum as first-line treatment for advanced non-squamous non-small-cell lung cancer (nsqNSCLC): A single-arm multicenter phase II study

Annals of oncology, 2023-10, Vol.34, p.S828-S829

2023

Volltextzugriff (PDF)

1049P Phase Ib/II trial of envafolimab, a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, plus lenvatinib in patients with selected advanced solid tumors

Annals of oncology, 2023-10, Vol.34, p.S635-S635

2023

Volltextzugriff (PDF)

LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial

Annals of oncology, 2022-09, Vol.33, p.S1384-S1385

2022

Volltextzugriff (PDF)

LBA22 Neoadjuvant chemotherapy with oxaliplatin and capecitabine versus chemoradiation with capecitabine for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Initial results of a multicenter randomised, open-label, phase III trial

Annals of oncology, 2021-09, Vol.32, p.S1296-S1296

2021

Volltextzugriff (PDF)

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Annals of oncology, 2024-01, Vol.35 (1), p.107-117

2024

Volltextzugriff (PDF)

Clonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer

Annals of oncology, 2019-10, Vol.30, p.v237

2019

Volltextzugriff (PDF)

626PClonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

626P - Clonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer

Annals of oncology, 2019-10, Vol.30, p.v237-v237

2019

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(79)

Publikationsform

Artikel
(79)

Sprache

Englisch
(79)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(5)
Oncology
(5)
Science & Technology
(5)
Humans
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Disease-Free Survival
(3)
Treatment Outcome
(3)
Adult
(2)
Aged
(2)
Antibodies, Monoclonal, Humanized
(2)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(2)
Asian
(2)
Egfr Mutation-Positive
(2)
Erlotinib
(2)
Female
(2)
First-Line
(2)
Kaplan-Meier Estimate
(2)
Male
(2)
Middle Aged
(2)
Nsclc
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

1947P Predictors and outcomes of recurrent retroperitoneal liposarcoma: New insights into its recurrence patterns

Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

1410P Efficacy of fruquintinib plus paclitaxel (F+PTX) in patients (pts) with prior immunotherapy (prior-IO): Subgroup analysis from FRUTIGA study

648P An open-label, MRCT phase I/II study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of first-in-class bi-ligand-drug conjugate CBP-1019 in patients (pts) with advanced solid tumors

Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)

77MO A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors

220O RATIONALE-309: Effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC)

VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy

Phase II trial of tepotinib vs sorafenib for treatment-naïve advanced hepatocellular carcinoma (HCC) in Asian patients

584P Two-year update of the prospective evaluation of ColonAiQ (PreC) study

1998P Antitumor activity and safety profile of trilaciclib in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC) receiving chemotherapy (TRACES): Updated results from TRACES

853P The germline mutation landscape of DDR genes in Chinese patients with epithelial ovarian cancer

1461P Analysis of MET gene alterations in cfDNA samples from a phase II study of savolitinib in patients (pts) with MET-amplified gastroesophageal junction adenocarcinomas or gastric cancer (GEJ/GC)

392P A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer

P-009Inhibition of Gastrointestinal Neuroendocrine Tumor by A New Marker of Normal Neuroendocrine Cells

1458P Pucotenlimab (HX008) - humanized anti-PD-1 monoclonal antibody plus pemetrexed and platinum as first-line treatment for advanced non-squamous non-small-cell lung cancer (nsqNSCLC): A single-arm multicenter phase II study

1049P Phase Ib/II trial of envafolimab, a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, plus lenvatinib in patients with selected advanced solid tumors

LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial

LBA22 Neoadjuvant chemotherapy with oxaliplatin and capecitabine versus chemoradiation with capecitabine for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Initial results of a multicenter randomised, open-label, phase III trial

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Clonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer

626PClonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer

626P - Clonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer

Aktive Filter

Suchergebnisse filtern